A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 with Open-label Extension in Ambulatory Patients with Duchenne Muscular Dystrophy (DYSTANCE 51)
Phase of Trial: Phase II/III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Suvodirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Acronyms DYSTANCE 51
- Sponsors WaVe life Sciences
- 02 Oct 2019 Planned End Date changed from 1 Aug 2021 to 1 Dec 2022.
- 02 Oct 2019 Planned primary completion date changed from 1 Aug 2021 to 1 Dec 2021.
- 16 Sep 2019 According to a Wave life sciences media release, this study is also the first ever selected by the FDA for its Complex Innovative Trial Design (CID) pilot program.